Alpha Tau Medical Jumps 19% After 3-Patient Brain-Cancer Trial Shows 2 Complete Responses
Updated
Updated · MarketWatch · May 11
Alpha Tau Medical Jumps 19% After 3-Patient Brain-Cancer Trial Shows 2 Complete Responses
7 articles · Updated · MarketWatch · May 11
$10.14 premarket trading put Alpha Tau shares up 19% after the company released interim data from a recurrent glioblastoma trial of its Alpha DaRT therapy.
Three patients were evaluated: two had continued complete responses with all enhancing tumor lesions gone, while the third showed stable disease and a 30% reduction in tumor size.
No patients had local or distant recurrence or residual procedure symptoms as of the cutoff date, adding to the company’s claim that the early results were groundbreaking.
Glioblastoma remains one of the deadliest treatment-resistant cancers, with average survival of about 8 months, underscoring why even early positive data drew a sharp market reaction.
With promising results but a serious side effect, will Alpha DaRT's safety profile derail its path to approval?
Can a tiny three-patient trial truly signal a breakthrough against the most untreatable and deadly brain cancer?
Beyond killing tumor cells, does this new therapy also awaken the immune system to prevent the cancer’s return?
Alpha Tau Medical’s Alpha DaRT Shows Promising Early Safety in U.S. REGAIN Trial for Recurrent Glioblastoma: Interim Results and Market Impact
Overview
Alpha Tau Medical announced interim safety results from its U.S. REGAIN trial for recurrent glioblastoma in May 2026, following an FDA request for early analysis. The report focused on the safety of Alpha DaRT treatment in the first three patients, who received therapy between December 2025 and March 2026. As of the May 3, 2026 data cutoff, no unexpected serious adverse events were observed, and only one grade 3 event was reported, suggesting a manageable safety profile. While these early results are promising, the small patient group means more data is needed to confirm long-term safety and effectiveness.